References
- 1. Lavebratt C, Alpman A, Persson B, Arner P, Hoffstedt J. Common neuropeptide Y2 receptor gene variant is protective against obesity among Swedish men. Int J Obes. 2006; 30(3): 453-459.
- 2. Suchanek P, Kralova-Lesna I, Pledne R, Lanska V, Hubacek JA. An AHSG gene variant modulates baal metabolic rate and body composition development after a short-time lifestyle intervention. Neuroendocrinol Lett. 2011; 32(suppl 2): 32-36.
- 3. Dahlman I, Eriksson P, Kaaman M, Jiao H, Lindgren CM, Kere J, et al. a2-Heremans-Schmid glycoprotein gene polymorphisms are associated with adipocyte insulin action. Diabetologia. 2004; 47(11): 1974-1979.
- 4. Siddiq A, Lepretre F, Hercberg S, Froguel P, Gibson F. A synonymous coding polymorphism in the a2-Here-mans-schmid glycoprotein gene is associated with type 2 diabetes in French Caucasians. Diabetes. 2005; 54(8): 2477-2481.
- 5. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Kröber SM, et al. a2-Heremans-Schmid glyco-protein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care. 2006; 29(4): 853-857.
- 6. Fisher E, Stefan N, Saar K, Drogan D, Schulze MB, Fritsche A, et al. Association of AHSG gene polymor-phisms with fetuin-A plasma levels and cardiovascular diseases in the EPIC-Potsdam study. Circ Cardiovasc Genet. 2009; 2(6): 607-613.
- 7. Muendlein A, Stark N, Rein P, Saely CH, Geller- Rhomberg S, Geiger K, et al. Are AHSG polymorphisms directly associated with coronary atherosclerosis? Clin Chim Acta. 2012; 413(1-2): 287-290.
- 8. Andersen G, Burgdorf KS, Sparsø T, Borch- Johnsen K, Jørgensen T, Hansen T, et al. AHSG tag single nucleotide polymorphisms associate with type 2 diabetes and dyslipidemia: studies of metabolic traits in 7,683 white Danish subjects. Diabetes. 2008; 57(5): 1427-1432.
- 9. Mathews ST, Singh GP, Ranalletta M, Cintron VJ, Qiang X, Goustin AS, et al. Improved insulin sensitivity and resistance to weight gain in mice null for the AHSG gene. Diabetes. 2002; 51(8): 2450-2458.
- 10. Ganjavi H, Shapiro CM. Hypocretin/Orexin: a molecular link between sleep, energy regulation, and pleasure. J Neuropsychiatry Clin Neurosci. 2007; 19(4): 413-419.
- 11. Sakurai T, Moriguchi T, Furuya K, Kajiwara N, Nakamura T, Yanagisawa M, et al. Structure and function of human prepro-orexin gene. J Biol Chem. 1999; 274(25): 17771-17776.
- 12. de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, et al. The hypocretins: hypothalamus- specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA. 1998; 95(1): 322-327.
- 13. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998; 92(4): 573-585.
- 14. Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, Sinton CM, et al. Genetic ablarton of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuwron. 2001; 30(2): 345-354.
- 15. Bronsky J, Nedvidkova J, Zamrazilova H, Pechova M, Chada M, Kotaska K, et al. Dynamic changes of orexin A and leptin in obese children during body weight reduction. Physiol Res. 2007; 56(1): 89-96.
- 16. Adam JA, Menheere PPCA, Van Dielen FMH, Soeters PB, Buurman WA, Greve JWM. Decreased plasma orexin-A levels in obese individuals. Int J Obes Relat Metab Disord. 2002; 26(2): 274-276.
- 17. Kok SW, Meinders AE, Overeem S, Lammers GJ, Roelfsema F, Frölich M, et al. Reduction of plasma leptin levels and loss of its circadian rhythmicity in hypocretin (orexin)-deficient narcoleptic humans. J Clin Endocrinol Metab. 2002; 87(2): 805-809.
- 18. Hungs M, Lin L, Okun M, Mignot E. Polymorphisms in the vicinity of the hypocretin/orexin are not associated with human narcolepsy. Neurology. 2001; 57 (10): 1893-1895.
- 19. Ammar DA, Eadie DM, Wong DJ, Ma Y-Y, Kolakowski LF Jr, Yang-Feng TL, et al. Characterization of the human type 2 neuropeptide Y receptor gene (NPY2R) and localization to the chromosome 4q region containing the type 1 neuropeptide Y receptor gene. Genomics. 1996; 38(3): 392 398.
- 20. Chen C-H, Stephens RL Jr, Rogers RC. PYY and NPY: control of gastric motility via action on Y1 and Y2 receptors in the DVC. Neurogastroenterol Mot. 1997; 9(2): 109-116.
- 21. Siddiq A, Gueorguiev M, Samson C, Hercberg S, Heude B, Levy-Marchal C, et al. Single nucleotide polymorphisms in the neuropeptide Y2 receptor (NPY2R) gene and association with severe obesity in French white subjects. Diabetologia. 2007; 50(3): 574-584.
- 22. Hunt SC, Hasstedt SJ, Xin Y, Dalley BK, Malish BA, Yakobson E, et al. Polymorphisms in the NPY2R gene show significant associations with BMI that are additive to FTO, MC4R, and NPFFR2 gene effects. Obesity. 2011; 19(11): 2241-2247.
- 23. Hung Ch-ChC, Pirie F, Luan J, Lank E, Motala A, Yeo GSH, et al. Studies of the peptide YY and neuropep-tide Y2 receptor genes in relation to human obesity and obesity-related traits. Diabetes. 2004; 53(9): 2461-2466.
- 24. Tunstall-Pedoe H. MONICA’s quarter century. Eur J Cardiovasc Prev Rehabil. 2003; 10(6): 409-410.
- 25. Thunsdall-Pedoe H, Kuulasmaa K, Tolonen H, Davidson M, Mendis S. MONICA monograph and multimedia sourcebook. Thunsdall-Pedoe H, Ed. Geneva: World Health Organization, 2003.
- 26. Ishibashi A, Ikeda Y, Ohguro T, Kumon Y, Yamanaka S, Takata H, et al. Serum fetuin-A is an independent marker of insulin resistance in Japanese men. J Atheroscler Thromb. 2010; 17(9): 925-933.
- 27. Singh M, Sharma PK, Garg VK, Mondal SC, Singh AK, Kumar N. Role of fetuin-A in atherosclerosis associated with diabetic patients. J Pharm Pharmacol. 2012; 64(12): 1703-1708.